Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan

Pfizer

Status

Completed

Conditions

Renal Cell Carcinoma

Study type

Observational

Funder types

Industry

Identifiers

NCT02776644

A6181222

Details and patient eligibility

About

The clinical outcome of advanced / metastatic renal cell carcinoma has been changed since targeted therapy being widely applied. This study will retrospectively analyse the clinical outcome of advanced renal cell carcinoma captured in Taiwan National Health Insurance Research Database.

Full description

Targeted therapy agents have significantly changed the clinical outcome of advanced / metastatic renal cell carcinoma. However, the dosing pattern varied and might result in impact to duration of treatment. In Taiwan, National Health Insurance system has a coverage more than 90% of population and thus can serve as an appropriate database for further analysis on Taiwanese advanced renal cell carcinoma. This study will retrospectively analyse the clinical outcome of advanced renal cell carcinoma captured in Taiwan National Health Insurance Research Database.

Enrollment

1,349 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria